|1.||Davis, Barry R: 27 articles (01/2016 - 04/2005)|
|2.||ALLHAT Collaborative Research Group: 18 articles (01/2016 - 02/2001)|
|3.||Ford, Charles E: 17 articles (01/2016 - 04/2005)|
|4.||Einhorn, Paula T: 11 articles (01/2016 - 01/2007)|
|5.||Cushman, William C: 11 articles (11/2014 - 04/2005)|
|6.||Whelton, Paul K: 11 articles (05/2013 - 04/2005)|
|7.||Wright, Jackson T: 11 articles (05/2013 - 04/2005)|
|8.||Oparil, Suzanne: 10 articles (01/2016 - 09/2006)|
|9.||Remuzzi, Giuseppe: 10 articles (01/2015 - 05/2002)|
|10.||Haywood, L Julian: 9 articles (01/2016 - 04/2005)|
|1.||Hypertension (High Blood Pressure)
02/01/1997 - "The efficacy of lisinopril in reducing blood pressure is well established in younger populations, and many trials now show it to be effective in lowering blood pressure in elderly patients with hypertension. "
12/01/2001 - "In conclusion, supervised lisinopril therapy is effective in controlling hypertension in chronic HD patients. "
01/01/1994 - "The main objective of this multicenter study was to compare the efficacy of an increase in dose and of a synergic combination in the 68 patients out of 126 (54%) with hypertension (DBP between 95 and 120 mm Hg after 2 weeks of placebo) who did not respond (DBP > or = 95 mmHg) to a 4-week treatment of 20 mg per day of lisinopril. "
01/01/1990 - "Thus, lisinopril at 20 or 40 mg once daily proved both well tolerated and effective in reducing blood pressure in patients with mild to moderate essential hypertension."
03/01/1993 - "The results of the efficacy analysis confirm the established efficacy of lisinopril in patients with mild to moderate essential hypertension."
12/01/2000 - "An analysis was designed to determine whether chronic heart failure patients at high cardiovascular risk benefited to the same extent from high-dose lisinopril as the whole ATLAS population. "
04/01/1998 - "ATLAS: high dose lisinopril is superior to low dose in heart failure."
08/20/2000 - "A prospective study was performed in patients (30 M, 16 F, mean age of 56.0 +/- 9.2 [42-73] years) with congestive heart failure to assess the efficacy of lisinopril during a 16 weeks treatment period. "
09/01/2002 - "Twelve patients with symptomatic heart failure completed a randomized double-blind crossover trial of lisinopril 5 mg o.d. "
04/01/2001 - "The objective of this sub-study of the ATLAS trial was to determine if there was a difference in effect on systolic blood pressure variability of two doses (35mg, 'high'; and, 5mg, 'low') of the ACE inhibitor, lisinopril, in patients with heart failure (class II-IV; NYHA). "
05/01/2000 - "Lisinopril is safe and effective when given early after the onset of myocardial infarction, regardless of a concomitant administration of ASA started early and continued over a 6-week period."
08/01/2005 - "In the Antihypertensive and Lipid Lowering to Prevent Heart Attack Trial, lisinopril-treated patients had a slightly lower incidence of myocardial infarction, despite much poorer control of blood pressure, perhaps because a second-line diuretic was prohibited by protocol. "
05/01/2000 - "The aim of the study was to verify the possible negative interaction between ASA and the ACEi lisinopril in the postacute phase of acute myocardial infarction. "
05/01/2000 - "The authors analyzed a database of 18,895 patients of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardio-3 (GISSI-3) Trial in which patients were allocated either to receive lisinopril or not to receive lisinopril within 24 hours of the onset of symptoms of myocardial infarction. "
12/16/1997 - "Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study."
01/01/1991 - "It has been shown in one study to decrease proteinuria as effectively as lisinopril, and it may have renal protective effects. "
09/01/2012 - "Lisinopril significantly reduced mean arterial blood pressure, and attenuated proteinuria level in patients subjected to this study in lisinopril 10mg dose dependent manner (p<0.05, n=24). "
01/01/1996 - "In the lisinopril- and in the ZD7155-treated rats, a comparable systolic pressure control was achieved (121 +/- 12 and 118 +/- 14 mm Hg, respectively), and proteinuria was significantly prevented (averaging only 38 +/- 23 and 30 +/- 8 mg/24h, respectively) at the end of the study. "
10/01/2015 - "Treatment with lisinopril resulted in the immediate disappearance of proteinuria. "
07/01/2015 - "Treatment with lisinopril reduced hyperfiltration, proteinuria and renal injury in Dahl-STZ rats. "
06/01/2000 - "This study was designed to assess the long-term effects of lisinopril on mortality, cardiac function, and ventricular fibrosis after MI, in rats. "
07/01/1992 - "In treatment trials, where reactive fibrosis was established, lisinopril promoted regression of the fibrosis and therefore was cardioprotective. "
08/01/2002 - "Lisinopril exerted a potent antiproteinuric effect and suppressed the progression of both glomerulosclerosis and tubulointerstitial fibrosis. "
08/01/1996 - "Lisinopril-mediated regression of myocardial fibrosis."
04/01/1992 - "With a low dose of lisinopril that does not reduce blood pressure significantly, only the excessive fibrosis is reversed. "
|1.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|8.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
|10.||Calcium Channels (Calcium Channel)
|1.||Transplantation (Transplant Recipients)